Meiragtx Holdings (MGTX) AI Stock Analysis

• Market Cap: $603.54M
• Dividend Yield: N/A
• Average Volume (3M): 444.85K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.82
• Revenue Growth: 203.23%
• EPS Growth: -80.71%
• Country: US
• Employees: 375
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.51
• Shares Outstanding: 80,365,360
• 10 Day Avg. Volume: 471,985
• 30 Day Avg. Volume: 444,848
• PEG Ratio: -0.02
• Price to Book (P/B): 2.50
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.49
• Enterprise Value/Market Cap: 0.45
• Enterprise Value/Revenue: 3.02
• Enterprise Value/Gross Profit: 21.51
• Enterprise Value/Ebitda: -0.52
• 1Y Price Target: $25.67
• Price Target Upside: 241.81% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 63 Neutral
• Price Target: $8.00 ▲(6.52%Upside)

Meiragtx Holdings' overall score is driven by strong technical momentum and positive corporate events, notably the FDA RMAT designation. However, significant financial challenges, including negative profitability and valuation metrics, weigh heavily on the overall score. Investors should be mindful of potential volatility due to the high-risk biotech nature.

Meiragtx Holdings Business Overview & Revenue Model

Company Description

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.

How the Company Makes Money

MeiraGTx Holdings makes money primarily through the development and commercialization of its gene therapy products. The company generates revenue through collaborative agreements, licensing arrangements, and milestone payments from partnerships with other pharmaceutical and biotechnology companies. These collaborations often involve co-development and commercialization efforts, allowing MeiraGTx to leverage external resources and expertise while receiving financial support. Additionally, as the company advances its product candidates through clinical trials and towards market approval, it may receive research funding and grants to support its development activities. Revenue growth is also expected to come from the eventual commercialization of its gene therapy products once they receive regulatory approval.

Meiragtx Holdings Financial Statement Overview

Summary

MeiraGTx Holdings faces typical financial challenges for early-stage biotech firms, with ongoing operating losses and reliance on external funding. Despite some revenue growth and improved leverage, profitability metrics remain negative. The balance sheet reflects financial instability with declining equity.

Income Statement

Meiragtx Holdings has shown a modest revenue growth with a TTM revenue of $34.51M, up from $33.28M in 2024. However, the company continues to face significant profitability challenges, with negative EBIT and EBITDA margins indicating operating losses. The net profit margin remains negative, underscoring ongoing financial losses, which is a common challenge in the biotechnology sector as companies invest heavily in R&D.

Balance Sheet

The company's debt-to-equity ratio has improved, reflecting a reduced leverage position. However, the equity ratio has decreased, indicating a lower proportion of equity funding relative to total assets. Despite a positive net debt position, the overall financial stability remains a concern due to declining stockholders' equity and substantial liabilities.

Cash Flow

Meiragtx Holdings' cash flow situation shows significant negative free cash flow, driven by high capital expenditures and negative operating cash flow. While there has been an influx of cash from financing activities, the reliance on external funding could pose sustainability issues in the long term. The operating cash flow to net income ratio reflects the ongoing cash burn typical in early-stage biotech firms.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	34.51M	33.28M	14.02M	15.92M	37.70M	15.56M
Gross Profit	12.61M	9.49M	14.02M	7.20M	29.83M	15.56M
EBITDA	-141.78M	-121.69M	-57.05M	-115.95M	-71.40M	-53.68M
Net Income	-167.33M	-147.79M	-84.03M	-142.88M	-71.98M	-53.96M
Balance Sheet
Total Assets	224.01M	269.75M	326.74M	318.24M	320.16M	363.70M
Cash, Cash Equivalents and Short-Term Investments	66.52M	103.66M	129.57M	115.52M	137.70M	209.52M
Total Debt	3.30M	84.80M	89.26M	92.25M	23.73M	22.25M
Total Liabilities	190.91M	201.92M	188.57M	200.50M	134.76M	125.14M
Stockholders Equity	33.10M	67.83M	138.18M	117.74M	185.40M	238.56M
Cash Flow
Free Cash Flow	-109.57M	-109.45M	-125.54M	-118.06M	-65.75M	-100.99M
Operating Cash Flow	-104.58M	-104.50M	-105.36M	-73.10M	-10.53M	-63.97M
Investing Cash Flow	-5.57M	23.48M	34.03M	-44.96M	-61.72M	-37.02M
Financing Cash Flow	57.52M	54.53M	84.02M	95.20M	1.71M	82.73M

Meiragtx Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.51
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MGTX, the sentiment is Positive. The current price of 7.51 is above the 20-day moving average (MA) of 6.51, above the 50-day MA of 6.05, and above the 200-day MA of 6.06, indicating a bullish trend. The MACD of 0.30 indicates Negative momentum. The RSI at 71.28 is Negative, neither overbought nor oversold. The STOCH value of 79.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MGTX.

Meiragtx Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MGTX	63 Neutral	$603.54M	―	-216.14%	―	203.23%	-80.71%
TBPH	57 Neutral	$557.51M	―	-31.46%	―	6.11%	-37.79%
CAPR	52 Neutral	$468.51M	―	-75.39%	―	-35.92%	-62.11%
AKBA	49 Neutral	$950.74M	―	91.25%	―	-17.75%	-19.17%
Sector *	49 Neutral	AU$2.49B	4.37	-64.25%	2.83%	36.51%	13.14%
QURE	47 Neutral	$789.47M	―	-241.16%	―	6.30%	29.17%
KROS	46 Neutral	$546.28M	―	0.71%	―	91657.69%	97.21%

Meiragtx Holdings Corporate Events

MeiraGTx Gains UK Approval for Hologen Transactions

MeiraGTx Holdings plc has received the necessary clearances and approvals under the UK’s foreign direct investment laws for its proposed transactions with Hologen Limited, which were initiated on March 9, 2025. These transactions are anticipated to conclude in July 2025, potentially impacting the company’s operational and strategic positioning in the market.

The most recent analyst rating on (MGTX) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Meiragtx Holdings stock, see the MGTX Stock Forecast page.

MeiraGTx Holdings Receives FDA RMAT Designation for AAV-GAD

On May 9, 2025, MeiraGTx Holdings announced that the FDA granted RMAT designation to AAV-GAD for treating Parkinson’s disease, based on positive data from clinical studies. This designation facilitates accelerated approval processes and highlights the potential of AAV-GAD as a one-time treatment, offering significant benefits for Parkinson’s patients not adequately controlled by existing medications.